Physician profile
Sarah E Weatherspoon
NPI 1407021389
$103,130.92
in general payments reported to CMS, 2019-2025
21 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,054 · 2020: $68.85 · 2021: $59.16 · 2022: $6,463 · 2023: $41K · 2024: $24K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Travel and Lodging: $17K · Consulting Fee: $5,985 · Food and Beverage: $4,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,920.00 |
| Travel and Lodging | $17,146.27 |
| Consulting Fee | $5,985.00 |
| Food and Beverage | $4,434.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $78,330.63 | 2022-2025 | Valtoco |
| Ucb, INC. | $19,982.46 | 2020-2025 | Fintepla, Briviact, Nayzilam |
| Mallinckrodt Enterprises LLC | $1,799.81 | 2019 | |
| Neuropace, INC. | $732.71 | 2022-2025 | |
| Upsher-Smith Laboratories LLC | $562.90 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $475.54 | 2024-2025 | Daybue |
| Jazz Pharmaceuticals INC. | $289.00 | 2022-2024 | |
| Livanova USA, INC. | $205.17 | 2019-2022 | |
| Sk Life Science, INC. | $154.75 | 2020-2025 | |
| Ptc Therapeutics, INC. | $125.00 | 2022 | |
| Greenwich Biosciences, INC. | $83.49 | 2019 | |
| Itf Therapeutics LLC | $68.34 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $66.42 | 2025 | |
| Immedica Pharma US, INC. | $45.19 | 2024-2025 | Ztalmy |
| Azurity Pharmaceuticals, INC. | $41.22 | 2022-2025 | Zonisade |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $38.60 | 2023-2025 | Diacomit |
| Otter Pharmaceuticals, LLC | $37.19 | 2025 | Sympazan |
| Supernus Pharmaceuticals, INC. | $34.94 | 2020 | |
| Eisai INC. | $30.21 | 2021-2022 | |
| Travere Therapeutics, INC. | $14.75 | 2019 | |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Weatherspoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.